Markets:

Overview

News

Currencies

International

Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

15.77 +0.12 (+0.76%)

Streaming Delayed Price Updated: 2:40 PM EST, Dec 29, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

The Next Big Buyout? Abivax Emerges as a Premier M&A Contender for 2026 Amidst Biotech Consolidation Wave

December 23, 2025

As the biotech sector closes out a transformative 2025, one name has risen to the top of every institutional investor's watchlist: Abivax (NASDAQ: ABVX). Following a year of stellar clinical results...

Via MarketMinute

Topics Intellectual Property

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

December 18, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Earnings Scheduled For July 30, 2025 ↗

July 30, 2025

Via Benzinga

Insights Ahead: Takeda Pharmaceutical's Quarterly Earnings ↗

July 29, 2025

Via Benzinga

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

December 06, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Pharmaceuticals’ Genetic Disease Therapy Under FDA Probe After Pediatric Patient Dies ↗

November 21, 2025

The death of a pediatric congenital thrombotic thrombocytopenic purpura patient appears to be related to Adzynma, the FDA said.

Via Stocktwits

Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile ↗

November 11, 2025

Neurocrine's Phase 2 trial of NBI-1070770 in major depressive disorder missed its main goal but showed good safety and strong Q3 financial results.

Via Benzinga

AI’s Next Frontier: Key Stocks to Watch Amidst Market Shifts and Technological Leaps

November 10, 2025

The artificial intelligence (AI) sector is currently navigating a period of unprecedented dynamism, characterized by explosive technological advancements, massive capital inflows, and a palpable...

Via TokenRing AI

Topics Artificial Intelligence

Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy

November 07, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....

Via MarketMinute

Topics Intellectual Property

New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization

November 03, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges ↗

October 30, 2025

Takeda posts lower Q2 earnings and trims 2025 outlook as Vyvanse generics, FX headwinds, and impairment charges weigh on revenue and profit.

Via Benzinga

Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year

October 30, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation

October 27, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors

October 21, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Taps Nabla Bio's Generative AI Platform For Antibody Design In $1 Billion Pact ↗

October 14, 2025

Nabla Bio partners with Takeda to use its AI platform JAM for designing antibodies, receiving upfront payments and potential success-based milestones.

Via Benzinga

Topics Artificial Intelligence

Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report ↗

October 10, 2025

Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug portfolio.

Via Benzinga

Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook

October 08, 2025

Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by...

Via MarketMinute

What's Going On With Nano-Cap Galecto Stock On Tuesday? ↗

October 07, 2025

Galecto stock spiked on heavy trading with no clear news, while the company highlights funding plans, pipeline updates, and clinical priorities.

Via Benzinga

20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries

September 23, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

5 Best High-Yield Dividend Stocks to Buy Now ↗

September 17, 2025

These five dividend stocks yield between 3.5% and 7.1%, but more importantly, they have the cash flows and business models to keep paying through the next downturn.

Via The Motley Fool

Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran

September 16, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit

September 11, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

September 08, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease

September 05, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

What's Going On With Takeda Stock On Friday? ↗

August 22, 2025

Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, posing fresh competition to Takeda's Takhzyro.

Via Benzinga

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder ↗

August 21, 2025

FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients.

Via Benzinga

Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales ↗

July 30, 2025

Takeda reported a 30% rise in Q1 profit and beat EPS estimates, offsetting Vyvanse losses with growth in oncology, plasma, and rare disease drugs.

Via Benzinga

Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression

July 30, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.